Search clinical trials for: Semaglutide placebo

Total 54152 results

Novo Nordisk A/S

Completed

A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes (SUSTAIN FORTE)

Diabetes Mellitus, Type 2

United States, Poland, Puerto Rico, Canada, Hungary, Greece, Japan, Bulgaria, Slovakia, Ukraine, Czechia
Novo Nordisk A/S

Completed

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese

Overweight or Obesity | Metabolism and Nutrition Disorders

United States
Novo Nordisk A/S

Completed

A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese

Obesity and Overweight

United States
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Kirsi Pietiläinen
Turku University Hospital; University of Helsinki

Recruiting

Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes (MitoSema)

Type2 Diabetes

Finland
Boehringer Ingelheim

Active, not recruiting

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906

Healthy | Obesity

Germany
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Recruiting

Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

Alcohol-related Liver Disease

Czechia, Denmark, Italy, Netherlands, Canada, Spain, United States, Australia, Japan, Greece, France, Poland, Bulgaria, Germany
Novo Nordisk A/S

Completed

Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People

Type 2 Diabetes | Healthy Volunteers

United States, Canada
Novo Nordisk A/S

Completed

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) (OASIS 1)

Obesity | Overweight

Germany, Denmark, Canada, United States, Russian Federation, Finland, Poland, France, Japan
University of North Carolina, Chapel Hill
National Institute on Drug Abuse (NIDA)

Recruiting

Effects of Semaglutide on Nicotine Intake

Tobacco Use Disorder | Nicotine Addiction

United States
Novo Nordisk A/S

Recruiting

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (PIONEER TEENS)

Diabetes Mellitus, Type 2

United States, Malaysia, United Kingdom, Australia, Netherlands, Portugal, Austria, Israel, India, Greece, Lebanon, Mexico, New Zealand, North Macedonia, Puerto Rico, Romania, Russian Federation, Ukraine, Morocco, Belgium, Czechia, Taiw...
Sansum Diabetes Research Institute
Novo Nordisk A/S

Terminated

Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care

Diabetes Mellitus, Type 2 | Glucose Metabolism Disorders (Including Diabetes Mellitus)

United States
Novo Nordisk A/S

Recruiting

A Study of How CagriSema Works on Appetite in People With Excess Body Weight

Obesity | Overweight

Germany
Novo Nordisk A/S

Completed

A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver

Non-alcoholic Fatty Liver Disease | Hepatobiliary Disorders

Germany
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People

Diabetes Mellitus, Type 2

Germany
Zuyderland Medisch Centrum
Nederlandse Obestias Kliniek (NOK)

Not yet recruiting

Semaglutide 2.4mg for Low Responders After Bariatric Surgery (SEABAR)

Obesity | Obesity, Morbid | Weight Gain
University of Tartu

Completed

The Effect of Semaglutide on Pituitary Function

Healthy

Estonia
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes (SUSTAIN™ 5)

Diabetes Mellitus, Type 2 | Diabetes

United States, Slovakia, Japan, Puerto Rico, Serbia, Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Austria
Shanghai Yinnuo Pharmaceutical Technology Co.,...
Shanghai 6th People's Hospital

Completed

A Study of Supaglutide in Chinese Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

China
University of Erlangen-Nürnberg Medical School

Recruiting

Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes (SEMA)

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin (PIONEER 8)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Japan, Puerto Rico, Canada, France, Mexico, Poland, Russian Federation, Greece
Novo Nordisk A/S

Completed

Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo

Obesity | Diabetes | Metabolism and Nutrition Disorder

United Kingdom
Novo Nordisk A/S

Completed

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity

Obesity & Overweight

Denmark, Canada
Novo Nordisk A/S

Completed

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, United Kingdom, Canada, Spain, Denmark, Austria, Serbia, South Africa, Sweden, Italy, Bulgaria, Germany, Malaysia
Novo Nordisk A/S

Recruiting

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (REIMAGINE 2)

Type 2 Diabetes Mellitus

Korea, Republic of, United States, Hungary, Serbia, Spain, China, Australia, Finland, United Kingdom, Italy, Denmark, Canada, Taiwan, Poland, Germany, Sweden, South Africa, India, Argentina, Brazil, Bulgaria, Japan, Mexico, Turkey, Greece, Colomb... and more
Novo Nordisk A/S

Active, not recruiting

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight (REDEFINE 2)

Obesity | Overweight | Type 2 Diabetes Mellitus

United States, India, Poland, Malaysia, United Kingdom, Japan, Thailand, Germany, Austria, Canada, Hungary, Ireland, Puerto Rico
Novo Nordisk A/S

Completed

Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity (STEP 8)

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Israel, Italy, Mexico, Poland, Russian Federation, Spain, Canada, Denmark, Taiwan, Malaysia, United Kingdom, Turkey, Germany, Bulgaria, Argentina, Australia, Thailand, Algeria, Brazil
Novo Nordisk A/S

Recruiting

A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight (REDEFINE 6)

Obesity or Overweight

China
Novo Nordisk A/S

Active, not recruiting

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight (REDEFINE 1)

Obesity

Finland, Spain, Taiwan, Korea, Republic of, United States, Netherlands, India, Japan, United Kingdom, Germany, Serbia, Denmark, Canada, Bulgaria, Australia, South Africa, Italy, Poland, Mexico, Belgium, Turkey, France, Argentina
Novo Nordisk A/S

Active, not recruiting

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis

Spain, Denmark, Taiwan, Korea, Republic of, Australia, Canada, India, Singapore, United States, Turkey, Poland, Italy, Belgium, Puerto Rico, United Kingdom, Malaysia, Germany, Portugal, Bulgaria, Czechia, France, Greece, Japan, Russian...
Shanghai Yinnuo Pharmaceutical Technology Co.,...

Active, not recruiting

A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients

Type2 Diabetes

China
Novo Nordisk A/S

Recruiting

Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) (SUSTAIN)

Diabetes Mellitus, Type 2 | Diabetes

Taiwan, Korea, Republic of, South Africa, Hong Kong, Brazil, China, Ukraine
Boehringer Ingelheim

Completed

A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

Diabetes Mellitus, Type 2

United States, Australia, Canada, Germany, Spain, Taiwan, Hungary, Poland, Korea, Republic of, Austria, New Zealand, United Kingdom, Czechia, Puerto Rico
University of California, San Diego

Recruiting

Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM (SAMARA)

Type 2 Diabetes Mellitus in Obese | Fibrosis, Liver | Non-Alcoholic Fatty Liver Disease

United States
Novo Nordisk A/S

Completed

Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity (STEP-HFpEF)

Obesity

United States, Spain, Australia, Hungary, United Kingdom, Netherlands, Canada, Argentina, Czechia, Germany, Denmark, Israel, Poland
Novo Nordisk A/S

Active, not recruiting

A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes (STRIDE)

Diabetes Mellitus, Type 2 | Peripheral Arterial Disease

Spain, Taiwan, China, India, United States, Canada, Thailand, Austria, Malaysia, Germany, Poland, Japan, Czechia, Greece, Belgium, Denmark, Hungary, Latvia, Norway, Sweden
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN 8)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, United Kingdom, Canada, Sweden, Ireland, Argentina, Brazil, Lebanon, Malaysia, Mexico, Italy
Novo Nordisk A/S

Completed

A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide

Obesity | Overweight | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Poland, Slovakia, Czechia
Novo Nordisk A/S

Completed

Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Diabetes Mellitus, Type 2 | Diabetes | Hepatic Impaired

Poland, Slovakia
Novo Nordisk A/S

Active, not recruiting

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

Early Alzheimer´s Disease

Canada, United States, Taiwan, Netherlands, United Kingdom, Spain, Austria, Korea, Republic of, Portugal, Italy, Australia, Argentina, Hungary, Germany, Brazil, China, Poland, Denmark, Czechia, Ireland, Japan, South Africa, Romania, S... and more

Search clinical trials for: Semaglutide placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations